The following active clinical trial (phase 2; NCT03367715) is a single-arm, open-label trial of Nivolumab combined with Ipilimumab and short-course radiotherapy in adult patients with newly diagnosed MGMT unmethylated GBM. The gene discussed is MGMT; the disease is glioblastoma.